Drugs / SMP-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05029518 | Sep → Nov 2021 | — | Chengdu SciMount Pharmatech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04296799 | Jun 2020 → Jul 2021 | — | Chengdu SciMount Pharmatech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SMP-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05029518 ↗ |
| Action | Activate | “partial agonist” NCT04296799 ↗ |
| Modality | Other / unclassified | “SMP-100 is a novel serotonin receptor 3 (5-HT3) partial agonist” NCT04296799 ↗ |
| Route | Oral | “oral administration SMP-100” NCT04296799 ↗ |